2003

December 18, 2003
Panacea Pharmaceuticals, Inc. and SRL, Inc. of Tokyo, Japan Announce Agreements to Develop and Commercialize HAAH Based Cancer Diagnostic Tests in Japan

December 9, 2003
Panacea Pharmaceuticals, Inc. and JSR Corporation Sign Collaborative Research Agreement for HAAH Cancer Diagnostics

November 20, 2003
Panacea Pharmaceuticals, Inc. Announces Presentations Detailing Advances in HAAH Oncology Program

November 12, 2003
Panacea Pharmaceuticals, Inc. Presents Data on Several Drug Candidates At Society for Neuroscience 33rd Annual Meeting

September 15, 2003
Panacea Pharmaceuticals, Inc. Signs License Agreement with Massachusetts General Hospital/Harvard University for SF-25 Oncology Program

September 10, 2003
Panacea Pharmaceuticals, Inc. Announces Extension of Collaboration With Massachusetts Institute of Technology to Engineer Antibodies for HAAH Oncology Program

July 7, 2003
Panacea Pharmaceuticals, Inc. Appoints Ambassador Diana Lady Dougan to its Board of Directors

June 25, 2003
Panacea Pharmaceuticals, Inc. Announces Appointment Of Bijan Almassian, PhD as Chief Operating Officer

May 13, 2003
Panacea Pharmaceuticals, Inc. Announces Formation of Proteus Diagnostics, Inc. to Develop and Commercialize Cancer Diagnostic Products

May 7, 2003
Panacea Pharmaceuticals, Inc. and Olympus Optical Co., Ltd. Sign Collaborative Research Agreement for MF20 System

April 9, 2003
Panacea Pharmaceuticals, Inc. Publishes New Findings on Diagnostic Applications of HAAH Oncology Program

February 26, 2003
Panacea Pharmaceuticals, Inc. Announces Opening of New Facility And Launch of New Website

January 21, 2003
Panacea Pharmaceuticals, Inc. Appoints Lawrence I. Glass As Chief Strategy Officer

January 13, 2003
Panacea Pharmaceuticals, Inc. Appoints Concetta E. Bartosh Vice-President for Legal Affairs

January 8, 2003
Panacea Pharmaceuticals, Inc. Announces Extension of Collaboration with Rhode Island Hospital/Brown University for HAAH Oncology Program